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We investigated the involvement of intracellular cAMP in endothelial cell injury induced by epirubicin.
Epirubicin-induced decrease in cell viability and increase in caspase-3/7 activity were reversed by a
cAMP analog dibutyryl cAMP (DBcAMP) or an activator of adenylate cyclase forskolin concomitant with a
phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine. Moreover, epirubicin-induced elevation of
lipid peroxide levels was attenuated by DBcAMP. Interestingly, the exposure of epirubicin decreased
intracellular cAMP levels before the onset of epirubicin-induced production of lipid peroxidation. These
results suggest that intracellular cAMP plays an important role in epirubicin-induced endothelial cell
injury.
© 2016 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Epirubicin has widely been used in the treatment of breast
cancer (1). The peripheral intravenous infusion of epirubicin
frequently causes venous irritation such as erythema, injection site
pain, and phlebitis (2). These vascular disorders deteriorate the
patient's quality of life and sometimes limit the continuation of
chemotherapy. Recently, we have shown that the injurious effects
of anticancer drugs on endothelial cells may be relevant as an in-
dicator of the frequency of vascular disorders (3). We also reported
that a transient exposure of epirubicin in endothelial cells induces
increase of oxidative stress and apoptotic cells, and that p38 MAPK
activation by oxidative stress is involved in epirubicin-induced
endothelial cell injury (4).
cAMP, a secondary messenger, is generated by ATP in mito-
chondria through intracellular signaling pathways. It has been re-
ported that the cAMP signaling cascade plays an important role in
regulation of apoptotic injury in a variety of cells via protein kinase
A (PKA) or exchange protein directly activated by cAMP (EPAC)
pathway (5e7). It has been shown that doxorubicin-induced car-
diomyocyte apoptosis is suppressed by the treatment of the cAMPyushu University Hospital, 3-
n. Tel.: þ81 92 642 5920;
.jp (N. Egashira).
rmacological Society.
. Production and hosting by Elseanalog, 8-bromo-cAMP (8-Br-cAMP), or adenylate cyclase activator,
forskolin (FSK) (8). Moreover, it is known that activation of cAMP/
PKA and AMP-activated protein kinase pathways inhibit palmitate-
induced apoptosis by suppression of reactive oxygen species (ROS)
generation (5).
Although, it has been demonstrated that the cAMP signaling
cascade plays an important role in regulation of apoptotic injury in
a variety of cells, the involvement of intracellular cAMP in
epirubicin-induced endothelial cell injury remain unclear. In this
study, we investigated the effect of a cAMP analog dibutyryl cAMP
(DBcAMP), an activator of adenylate cyclase FSK concomitant with a
phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX),
a PKA-selective cAMP analog 8-Br-cAMP, or an EPAC-selective
analog 8-pCPT-20-O-Me-cAMP on epirubicin-induced cell injury.
In addition, wemeasured caspase-3/7 activity, lipid peroxide levels,
and cAMP levels in endothelial cells.
Epirubicin, DBcAMP, IBMX, 8-Br-cAMP, and 8-pCPT-20-O-Me-
cAMPwere purchased from SigmaeAldrich Co. (St. Louis, MO, USA).
FSK was obtained from EMD Chemicals (San Diego, CA, USA).
Diphenyl-1-pyrenylphosphine (DPPP) was purchased from Dojindo
Lab (Kumamoto). Porcine aorta endothelial cells (PAECs) were ob-
tained from Dainippon Sumitomo Pharmaceutical Co., Ltd. (Osaka).
Cells were maintained in DMEM (MP Biomedicals, Inc., Irvine, CA,
USA) supplemented with 10% FBS, 100 U/ml penicillin, 100 mg/ml
streptomycin, and 250 ng/ml amphotericin B (GIBCO BRL, Grand
Island, NY, USA) at 37 C in 5% CO2 and 95% air.vier B.V. This is an open access article under the CC BY-NC-ND license (http://
Fig. 1. Effects of cAMP analogs and FSK þ IBMX on cell viability and caspase-3/7 activity in PAECs. Cells were exposed to epirubicin (30 mM) for 10 min and incubated for 24 h in the
absence of epirubicin. DBcAMP, FSK, IBMX, 8-Br-cAMP, and 8-pCPT-20-O-Me-cAMP were added 1 h before epirubicin treatment and were included throughout the experiment. (A),
(B), (C) Cell viability was assessed by WST-8 assay and (D), (E) caspase-3/7 activity was determined using the Apo-One Homogeneous Caspase-3/7 Assay. Data are expressed as the
means ± SEM of four experiments. **P < 0.01 vs. epirubicin alone.
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Fig. 2. Effect of DBcAMP on epirubicin-induced oxidative stress in PAECs. Cells were exposed to epirubicin (30 mM) for 10 min and incubated for 3e12 h in the absence of epirubicin.
DBcAMP was added 1 h before epirubicin treatment and was included for 12 h. The production of lipid hydroperoxides was measured by DPPP stains using ﬂuorescence microscopy.
(A) Representative images of four separate experiments were visualized under a ﬂuorescence microscope, and (B) the ﬂuorescence intensity was measured by image analyzer
software. Data are expressed as the means ± SEM of six experiments. **P < 0.01 vs. control. yyP < 0.01 vs. epirubicin (12 h).
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plates (Nalge Nunc International, Rochester, NY, USA). Cell viability
was assessed by measuring the mitochondrial activity that reduces
2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfoph
enyl)-2H-tetrazolium monosodium salt (WST-8) to formazan.
Brieﬂy, after treatment with epirubicin (30 mM) for 10 min, the cells
were washed with PBS and incubated for 24 h in serum-free me-
dium in the absence of epirubicin. cAMP analogs, FSK, and IBMX
were added 1 h before epirubicin treatment and were included
throughout the experiment. The cells were then incubated withWST-8 assay solution (Cell Counting Kit-8, Dojindo Lab.). The
amount of formed formazan was measured from the absorbance at
450 nmwith a reference wavelength of 620 nm using a microplate
absorbance reader (Rainbow Sunrise; Tecan Austria GmbH, Salz-
burg, Austria).
Caspase-3/7 activity was determined using the Apo-One Ho-
mogeneous Caspase-3/7 Assay (Promega, Madison,WI, USA). PAECs
were cultured on 96-well ﬂat-bottom plastic plates (Corning, Inc.,
Corning, NY, USA) at 0.3  104 cells/well. Cells were exposed to
epirubicin (30 mM) for 10min and then incubated for 24 h. Caspase-
Fig. 3. Involvement of intracellular cAMP levels in epirubicin-induced cell injury in
PAECs. Cells were exposed to epirubicin (30 mM) for 10 min and incubated for each
time in the absence of epirubicin. Measurement of intracellular cAMP levels was
performed using the cAMP-Glo assay. Data are expressed as the means ± SEM of three
separate experiments. **P < 0.01 vs. control.
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excitation wavelength of 490 nm and the emission wavelength of
530 nm using a ﬂuorescence microplate reader (MTP-601; Corona
Electric Co., Ltd., Ibaragi).
The epirubicin-induced generation of lipid hydroperoxides was
estimated from the oxidation of DPPP. PAECs were cultured on
eight-chamber plastic slides (Iwaki, Tokyo) at 0.8  104 cells/
chamber for ﬂuorescence microscopy analysis. Cells were incu-
bated for 3 h with 5 mMDPPP and exposed to epirubicin (30 mM) for
10 min and incubated for 3e12 h. Fluorescence images of DPPP
oxide were monitored using a ﬂuorescence microscope (BZ-9000;
Keyence, Osaka). For quantitative measurements, ﬁve areas were
chosen randomly from each well, and the ﬂuorescence intensity
was measured and analyzed by BZ-II ANALYZER software
(Keyence).
Measurement of intracellular cAMP levels was performed using
the cAMP-Glo assay (Promega, Madison, WI, USA). PAECs were
cultured on 96-well ﬂat-bottom plastic plates at 0.3  104 cells/
well. Cells were exposed to epirubicin (30 mM) for 10 min and then
incubated for 3e12 h. Plates were read using a microplate-reading
luminometer (Flexstation III, Molecular Devices, Sunnyvale, CA,
USA). Protein concentrations were determined using the DC Protein
Assay Kit (Bio-Rad Laboratories, Hercules, CA, USA).
Data were expressed as the means ± SEM. The data were
analyzed by one-way analysis of variance (ANOVA) followed by
TukeyeKramer post-hoc test. Statistical signiﬁcance was deﬁned as
P < 0.05.
As shown in Fig. 1, the exposure to epirubicin (30 mM) for 10 min
caused a signiﬁcant decrease in cell viability and a signiﬁcant in-
crease in caspase-3/7 activity (P < 0.01). The epirubicin-induced
decrease in cell viability was reversed by DBcAMP (1 and 3 mM),
FSK (3 and 10 mM) concomitant with IBMX (100 mM), or 8-Br-cAMP
(3 mM) (P < 0.05 or 0.01, Fig. 1A, B, C). On the other hand, the
epirubicin-induced decrease in cell viability was not reversed by 8-
pCPT-20-O-Me-cAMP (100 and 300 mM). The epirubicin-induced
increase in caspase-3/7 activity was reversed by DBcAMP (1 and
3mM) or FSK (10 mM) concomitant with IBMX (100 mM) (P < 0.05 or
0.01, Fig. 1D and E).
To examine the involvement of lipid peroxidation in the
epirubicin-induced cell injury, the production of lipid hydroper-
oxides was measured by DPPP stains using ﬂuorescence micro-
scopy. A marked increase in the number of cells revealing
ﬂuorescent DPPP oxide was observed at 12 h after transient expo-
sure to epirubicin, and the elevation of ﬂuorescence intensity of
DPPP oxide was inhibited by DBcAMP (P < 0.01, Fig. 2).
To examine the involvement of intracellular cAMP in the
epirubicin-induced cell injury, we measured intracellular cAMP
levels after transient exposure to epirubicin. As shown in Fig. 3, the
exposure of epirubicin (30 mM) for 10 min signiﬁcantly decreased
intracellular cAMP levels at 3 h (P < 0.05), 6 h (P < 0.05), and
12 h (P < 0.01) after exposure.
The incidence of vascular disorder after infusion of epirubicin
has been reported as approximately 40% (9). Epirubicin is generally
administered intravascularly for 10 min, and the epirubicin-
induced vascular disorder is usually caused at the injection site.
Because vascular endothelial cells are ﬁrst exposed to drugs
administered intravascularly, the endothelial cell dysfunction may
contribute to vascular disorders (10). Therefore, we investigated the
effect of transient exposure to epirubicin for 10 min on vascular
endothelial cell (4).
Intracellular cAMP levels are regulated by their synthesis by
adenylate cyclase and hydrolysis by phosphodiesterase (11). It has
been reported that the cAMP signaling cascade plays an important
role in regulation of apoptotic injury in a variety of cells via PKA or
EPAC pathway (5e7). In the present study, the elevation ofintracellular cAMP levels by DBcAMP or the enhancement of
endogenous cAMP levels by FSK and IBMX signiﬁcantly reversed
the decrease in cell viability and the increase in caspase activity
induced by epirubicin in PAECs. These results suggest that intra-
cellular cAMP plays an important role in the epirubicin-induced cell
injury. We also found that the epirubicin-induced decrease in cell
viability was reversed by 8-Br-cAMP but not 8-pCPT-20-O-Me-
cAMP. Therefore, PKA rather than EPAC may be involved in the
protective effect of cAMP.
In this study, the ﬂuorescence intensity of DPPP oxide was
enhanced 12 h after exposure of epirubicin, indicating that epi-
rubicin increases intracellular lipid peroxidation. We also found that
this epirubicin-induced production of lipid peroxidation was
inhibited by DBcAMP. Interestingly, our results showed that the
exposure of epirubicin signiﬁcantly decreased intracellular cAMP
levels before the onset of epirubicin-induced production of lipid
peroxidation. Therefore, the epirubicin-induced decrease in intra-
cellular cAMP levels may trigger oxidative stress. This idea is well
supported by previous studies that showcAMP analogs have an anti-
apoptotic effect and attenuate ROS production (12, 13), and intra-
cellular cAMP levels are reduced under ROS-generating conditions
(14). However, the mechanism of epirubicin-induced decrease in
intracellular cAMP levels is unclear. One possible mechanism is that
activation of inhibitory G protein inactivates adenylate cyclase
resulting in the reduction of cAMP levels (15), but there is no evi-
dence that epirubicin directly or indirectly activates the inhibitory G
protein in endothelial cells. On the other hand, cAMP is generated by
ATP in mitochondria through intracellular signaling pathway. Our
previous study indicated that epirubicin depolarized the mito-
chondrial membrane potential (4). Therefore, the reduction of ATP
production associated with the mitochondrial dysfunction may
contribute to the decrease of intracellular cAMP levels.
In conclusion, we showed that DBcAMP or FSK concomitant
with IBMX, inhibited epirubicin-induced cell damage and apoptosis
in endothelial cells. Moreover, epirubicin-induced production of
lipid peroxidation following decrease of intracellular cAMP levels
was attenuated by DBcAMP. These results indicate that intracellular
T. Yamada et al. / Journal of Pharmacological Sciences 130 (2016) 33e37 37cAMP may be a key factor in epirubicin-induced endothelial cell
injury.
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